Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Cancer Vaccines01:30

Cancer Vaccines

503
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
503

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Blood·2026
Same author

Simulating Cancer Recurrence Patterns From Post-Treatment Viable Tumor Burden Distributions.

JCO clinical cancer informatics·2026
Same author

Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

Cancer discovery·2026
Same author

Ancestral protein reconstruction reveals the mechanism of substrate specificity in FN3K-mediated deglycation.

Communications biology·2026
Same author

Cancer-selective photoimmunotherapy spares T cells and NK cells and promotes antitumor immunity in an allogeneic human 3D culture model.

Photochemistry and photobiology·2026
Same author

FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer.

Cancer immunology research·2026
Same journal

Systemic immune profiling in hepatocellular carcinoma: navigating etiological heterogeneity and selection bias.

Journal for immunotherapy of cancer·2026
Same journal

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same journal

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal for immunotherapy of cancer·2026
Same journal

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

Journal for immunotherapy of cancer·2026
Same journal

Metabolic inhibition of glutamate-cysteine ligase increases dendritic cell-mediated antitumor immunity in melanoma.

Journal for immunotherapy of cancer·2026
Same journal

Correction: CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell.

Journal for immunotherapy of cancer·2026
See all related articles

Related Experiment Video

Updated: Sep 5, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Rethinking the immunotherapy numbers game.

Rebecca A Bekker1,2, Mohammad U Zahid1, Jennifer M Binning3

  • 1Department of Integrated Mathematical Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.

Journal for Immunotherapy of Cancer
|July 6, 2022
PubMed
Summary
This summary is machine-generated.

Immunotherapies show promise in cancer treatment, but patient responses vary. Understanding the tumor microenvironment and integrating mathematical oncology can personalize treatment for better outcomes.

Keywords:
computational biologyimmunotherapy

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

655

Related Experiment Videos

Last Updated: Sep 5, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

655

Area of Science:

  • Oncology
  • Immunology
  • Mathematical Biology

Background:

  • Immunotherapies have revolutionized cancer treatment, offering significant response rates for certain malignancies.
  • Despite advances, predicting patient response to immunotherapy remains a challenge due to individual variations.
  • The tumor microenvironment and tumor-immune ecosystem play crucial roles in treatment efficacy, yet no specific immune biomarker exists to predict differential outcomes.

Purpose of the Study:

  • To investigate the factors influencing variable patient responses to cancer immunotherapies.
  • To explore the utility of integrated mathematical oncology approaches in understanding treatment dynamics.
  • To conceptualize how to optimize combination therapies for improved tumor control and reduced toxicity.

Main Methods:

  • Utilizing integrated mathematical oncology models to simulate treatment effects.
  • Analyzing the interplay between tumor cells and the immune microenvironment.
  • Developing a framework to predict patient-specific responses to immunotherapy and combination therapies.

Main Results:

  • Demonstrated the potential of mathematical oncology to model complex tumor-immune interactions.
  • Highlighted the importance of considering both tumor and immune states for predicting treatment success.
  • Provided a conceptual basis for personalizing immunotherapy and cytotoxic therapy combinations.

Conclusions:

  • Integrated mathematical oncology offers a novel approach to understand and predict patient responses to cancer immunotherapies.
  • A comprehensive understanding of the tumor-immune ecosystem is critical for optimizing treatment strategies.
  • Personalized combination therapies, guided by mathematical modeling, hold promise for improving cancer patient outcomes and minimizing toxicity.